Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry

BMC Cancer

Research Article

Damin Chai¹  Shiwu Wu¹  Yisheng Tao¹  Lan Yu¹  Lei Zhou¹  Danna Wang¹  Zenong Cheng¹  Li Ma¹ 

[1] Department of Pathology, the First Affiliated Hospital of Bengbu Medical College, Bengbu Medical College, 233000, Bengbu, Anhui Province, China;

关键词: Cancer Stem Cell;    NSCLC Cell;    Vasculogenic Mimicry;    CD133 Group;    Laryngeal Squamous Cell Carcinoma;   

DOI  :  10.1186/1471-2407-12-535

 received in 2012-01-30, accepted in 2012-11-14,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundTo investigate on expressions and clinical significances of CD133 protein and vasculogenic mimicry (VM) in primary non-small cell lung cancer (NSCLC).MethodsThe specimens of NSCLC from 305 Chinese patients with follow-up were analyzed for CD133 protein expression and VM by immunohistochemical and histochemical staining.ResultsIn NSCLC, positive rates of 48.9% and 35.7% were obtained for CD133 and VM, respectively. The VM and expression of CD133 were significantly higher in carcinoma than in normal. There were a positive relationship between the VM and expression of CD133 and the tumor grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with CD133 and VM positive expression was lower than that of patients with negative expression. Microvessel density (MVD) was positive corresponded with the grade, lymph node metastasis and clinical stage (all P<0.05). The overall mean survival time of the patients with MVD≥22’s group was shorter than that of patients with MVD<22’s group. Pathological-tumor-node-metastasis (pTNM) stage, positive expression of CD133 and VM, postoperative therapy and MVD were independent prognostic factors of NSCLC (P<0.05). Immunohistochemistry revealed an important intratumoral heterogeneity in all four CD133 expression profiles.ConclusionsVM, MVD and expression of CD133 are related to differentiation, lymph node metastasis, clinical stage, and prognosis. It is suggested that CD133, VM and MVD should be considered as a potential marker for the prognosis.

【 授权许可】

Unknown   
© Wu et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.